Inmune Bio CFO buys $49k in company stock

David J. Moss, the Chief Financial Officer of Inmune Bio, Inc. (NASDAQ:INMB ), a company specializing in biological products, has made a significant purchase of company stock, according to a recent SEC filing. The transaction, which took place on September 12, 2024, involved the acquisition of 7,690 shares of common stock at an average price of $6.375 per share, totaling approximately $49,023.


The purchase reflects Moss's confidence in the company, as it increases his direct ownership to 1,275,869 shares following the transaction. Moss, who also holds a position as a ten percent owner of the company, executed this buy in a registered direct offering at a price of $6.50 per share, with an aggregate purchase price of $13,000,000 as per the securities purchase agreement dated on the same day.


Moreover, in addition to the common stock, Moss acquired the same number of common stock warrants, with each warrant granting the right to buy additional shares at a price of $6.40, subject to certain adjustments as provided in the warrant. These warrants are exercisable starting from March 16, 2025, and will expire on March 16, 2030, unless exercised earlier under specific conditions outlined in the terms of the warrants.


Investors often monitor insider transactions such as these for insights into executive sentiment regarding their company's prospects. Inmune Bio's recent filings provide a clear signal of insider commitment to the firm's future, with the CFO's purchase representing a notable endorsement of the company's direction and potential.


For those interested in Inmune Bio's stock movements and insider transactions, the company trades under the ticker INMB on the NASDAQ exchange.



In other recent news, INmune Bio Inc. secured approximately $13 million in gross proceeds from a registered direct offering, which included the sale of common stock and corresponding warrants. The transaction involved both new and existing institutional investors, as well as company insiders. The net proceeds are earmarked for working capital and general corporate purposes, with A.G.P./Alliance Global Partners (NYSE:GLP ) serving as the sole placement agent for the offering.


In addition, Scotiabank initiated coverage on shares of INmune Bio with a Sector Outperform rating, citing compelling evidence from medical literature and early clinical results for the company's lead drug candidate, XPro. The bank's analysis emphasized the potential of XPro in the treatment of Alzheimer's disease.


Furthermore, INmune Bio reported promising developments in its INKmune memory-like natural killer cell oncology platform and its ongoing Phase II Alzheimer's study during its second quarter 2024 earnings call. The company also raised approximately $14.5 million in gross proceeds from equity offerings, ensuring sufficient funds for operations until 2025. These are the recent developments in INmune Bio's pursuit of advancing its clinical trials and bringing innovative treatments to the market.
InvestingPro Insights


In the wake of CFO David J. Moss's substantial investment in Inmune Bio, Inc. (NASDAQ:INMB), recent data from InvestingPro provides a broader context for understanding the company's financial health and market performance. Despite the confidence shown by Moss, InvestingPro Tips indicate that Inmune Bio holds more cash than debt on its balance sheet, which could be a sign of a solid financial foundation. Additionally, the company is described as a niche player in the biological products industry, which may offer unique advantages or challenges in its market segment.


InvestingPro Data further reveals that Inmune Bio has a market capitalization of approximately $105.72 million, with a negative P/E ratio of -2.59, reflecting challenges in profitability. The company's stock price has been volatile, with a significant decline over the past six months, currently trading near its 52-week low. This could be attributed to analysts' expectations of a sales decline and a drop in net income for the current year. Furthermore, Inmune Bio's stock has experienced a price total return of -50.63% over the past six months, which aligns with the tip that the stock has taken a big hit during this period.


For investors considering following the CFO's lead, it's worth noting that there are additional InvestingPro Tips available on the platform, providing deeper insights into Inmune Bio's financials and market performance. These tips could help investors make more informed decisions regarding their interest in INMB shares.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com